Isomorphic Labs, MSD Partner on Cancer Drug Design
The AI drug design company will use its proprietary engine alongside MSD's data to develop small molecule candidates against an oncology target.
Updated on Nov. 19, 2026 in Cancer

Isomorphic Labs and MSD, the trade name of Merck & Co., Inc., announced a research collaboration to develop therapeutic small molecule candidates against an oncology target of strategic importance. Isomorphic Labs will apply its drug design engine, IsoDDE, using proprietary data sets supplied by MSD.
Why it matters
The partnership pairs AI-driven molecular design with a large pharmaceutical company's proprietary data and discovery experience. The companies aim to identify new ways to design and create better candidates faster.
The collaboration terms include an upfront payment, milestone payments tied to research, development, regulatory and commercial events, and tiered royalties on net sales, with an option for Isomorphic Labs to co-fund development in exchange for elevated royalties. The announcement did not disclose dollar values, and the oncology target remains unnamed.
The players
Isomorphic Labs
Isomorphic Labs is an AI-first drug design and development company with offices in London, Cambridge, Massachusetts, and Lausanne, Switzerland.
MSD
MSD is the trade name of Merck & Co., Inc., a pharmaceutical company headquartered in Rahway, New Jersey, with a history of bringing medicines and vaccines to patients for 130 years.
The details
Isomorphic Labs will perform in silico predictions and deliver molecular designs, while MSD supplies select proprietary data sets and handles preclinical and clinical development, manufacturing and commercialisation of any resulting products.
Timeline
Isomorphic Labs was founded in 2021.
The collaboration was announced on November 19, 2026.
Health Landscape
The partnership extends Isomorphic Labs' IsoDDE drug design engine from in-house development into a collaboration with MSD's proprietary data. It reflects a broader pattern of AI-first design companies pairing computational models with large pharmaceutical data resources to accelerate oncology drug discovery.
Any candidates that emerge from this collaboration would need preclinical and clinical testing before reaching patients, a process that typically takes years. The announcement does not indicate when, or whether, a treatment could become available.
The takeaway
AI-driven drug design is increasingly being combined with large proprietary pharmaceutical datasets, a pairing that could shape how oncology candidates are identified in the years ahead. Readers should watch for named targets and disclosed milestones as the collaboration progresses.
Further reading
For more on how researchers are approaching treatment for the disease, see Cancer.
Source note: This article includes information reported by Adnkronos.



